JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Fechado

SetorSaúde

198.07 -0.35

Visão Geral

Variação de preço das ações

24h

Atual

Mín

198

Máximo

198.64

Indicadores-chave

By Trading Economics

Rendimento

1.3B

1.3B

Vendas

2.1B

15B

P/E

Médio do Setor

92.578

34.393

EPS

2.97

Rendimento de Dividendos

3.31

Margem de lucro

9.66

Funcionários

55,000

EBITDA

-4.3B

117M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+9.3% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.31%

2.54%

Próximos Ganhos

29 de out. de 2025

Próxima data de dividendos

15 de ago. de 2025

Próxima data de ex-dividendo

14 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

12B

348B

Abertura anterior

198.42

Fecho anterior

198.07

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

AbbVie Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de jul. de 2025, 12:46 UTC

Ganhos

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30 de jun. de 2025, 13:02 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 de abr. de 2025, 13:57 UTC

Ganhos

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 de abr. de 2025, 12:52 UTC

Ganhos

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31 de jul. de 2025, 12:08 UTC

Ganhos

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31 de jul. de 2025, 11:46 UTC

Ganhos

AbbVie Raises FY Outlook

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q Adj EPS $2.97 >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q EPS 52c >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q Rev $15.42B >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31 de jul. de 2025, 11:44 UTC

Ganhos

AbbVie 2Q Net $938M >ABBV

30 de jun. de 2025, 12:47 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 de jun. de 2025, 12:33 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 de jun. de 2025, 12:33 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 de jun. de 2025, 12:32 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 de jun. de 2025, 12:31 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 de mai. de 2025, 09:30 UTC

Principais Notícias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 de abr. de 2025, 12:44 UTC

Ganhos

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 de abr. de 2025, 09:33 UTC

Ganhos

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 de abr. de 2025, 16:03 UTC

Ganhos

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 de abr. de 2025, 14:00 UTC

Principais Notícias
Ganhos

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 de abr. de 2025, 12:24 UTC

Principais Notícias
Ganhos

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 de abr. de 2025, 12:03 UTC

Principais Notícias
Ganhos

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Comparação entre Pares

Variação de preço

AbbVie Inc Previsão

Preço-alvo

By TipRanks

9.3% parte superior

Previsão para 12 meses

Média 216.47 USD  9.3%

Máximo 255 USD

Mínimo 170 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para AbbVie Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

11

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

180.37 / 195.54Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.